Where can I buy shares of DCTH?
Shares of DCTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Should you buy Delcath Systems (DLC) stock?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Delcath Systems stock. View analyst ratings for Delcath Systems or view top-rated stocks.
Does Delcath Systems pay a dividend?
Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York. More... DCTH does not currently pay a dividend.
Who owns Delcath Systems'stock?
Delcath Systems' stock is owned by a variety of institutional and retail investors. Top institutional investors include CIBC World Markets Inc. (1. 16%), Susquehanna International Group LLP (0. 37%), State Street Corp (0. 34%) and Virtu Financial LLC (0. 20%).
Is Dcth a good stock to buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: DCTH) stock is to Strong Buy DCTH stock.
What happened to delcath?
The company was essentially forced to move to the OTC after its shareholders voted against a reverse split to regain NASDAQ compliance. Now, Delcath has made its way back onto the NASDAQ and is moving closer to an FDA approval for their PHP product candidate, HEPZATO.
Where is delcath systems located?
Queensbury, New YorkDelcath Systems, Inc. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver.
Should I buy or sell Delcath Systems stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 2...
What is Delcath Systems' stock price forecast for 2022?
2 equities research analysts have issued 12 month target prices for Delcath Systems' stock. Their forecasts range from $20.00 to $25.00. On average...
How has Delcath Systems' stock price performed in 2022?
Delcath Systems' stock was trading at $7.75 at the beginning of the year. Since then, DCTH shares have decreased by 47.4% and is now trading at $4....
When is Delcath Systems' next earnings date?
Delcath Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Delca...
How were Delcath Systems' earnings last quarter?
Delcath Systems, Inc. (NASDAQ:DCTH) announced its earnings results on Tuesday, May, 10th. The company reported ($1.00) EPS for the quarter, missing...
When did Delcath Systems' stock split? How did Delcath Systems' stock split work?
Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th...
Who are Delcath Systems' key executives?
Delcath Systems' management team includes the following people: Mr. Gerard J. Michel MBA , MS, CEO & Director (Age 59, Pay $683.82k) ( LinkedIn...
Who are some of Delcath Systems' key competitors?
Some companies that are related to Delcath Systems include LMF Acquisition Opportunities (LMAO) , iCAD (ICAD) , BrainsWay (BWAY) , Asensus Surg...
What is Delcath Systems' stock symbol?
Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH."
How many shares of Delcath Systems stock are there after the split?
When will Delcath release its next quarterly earnings?
An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 1 shares after the split.
How much does Delcath make?
Delcath Systems is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021. View our earnings forecast for Delcath Systems.
Is Delcath Systems (NASDAQ:DCTH) Weighed On By Its Debt Load?
How much money does Delcath Systems make? Delcath Systems has a market capitalization of $64.25 million and generates $1.16 million in revenue each year. The company earns $-24,160,000.00 in net income (profit) each year or ($8.35) on an earnings per share basis.
Will Delcath Systems, Inc. (DCTH) Report Negative Earnings Next Week? What You Should Know
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Moving Average Crossover Alert: Delcath Systems (DCTH)
Delcath Systems, Inc. (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Who Has Been Buying Delcath Systems, Inc. (NASDAQ:DCTH) Shares?
Delcath Systems (DCTH) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
54 Biggest Movers From Yesterday
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
61 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
40 Stocks Moving In Thursday's Mid-Day Session
Gainers Jowell Global Ltd. (NASDAQ: JWEL) jumped 25.5% to close at $13.36. Jowell Global recently announced a collaboration with Unilever's Uni-Excubator.
Delcath Systems (NASDAQ:DCTH) Price Target and Consensus Rating
Gainers Biofrontera Inc. (NASDAQ: BFRI) surged 39% to $6.02. Biofrontera announced Notice of Allowance for U.S. patent titled 'Illumination for Photodynamic Therapy.'
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Delcath Systems (NASDAQ:DCTH) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
What is Delcath system?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Delcath Systems stock is Buy based on the current 3 buy ratings for DCTH. The average twelve-month price target for Delcath Systems is $24.33 with a high price target of $25.00 and a low price target of $23.00. Learn more on DCTH's analyst rating history
What time do you trade in the pre market?
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Does market cap include convertible securities?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
When did the stock move to the OTCQB?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Where is Delcath Systems located?
Securities were listed on both the NASDAQ and Boston Stock Exchange. The stock moved from the NASDAQ to the OTCQB on September 15, 2017 after the company Voluntarily Delisted it from NASDAQ and requested an Accelerated listing in the OTC marketplace. Stock Split History.